Clinical trial
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
NCT04389580 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
- Lead sponsor
- Kafrelsheikh University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 30, 2021
- Completion date
- December 31, 2021
- Enrollment
- 160 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.